Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03471481

Enrollment

Registered

2018-03-20

Start date

2015-08-10

Completion date

2019-08-01

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Magnesium Deficiency, Vitamin D Deficiency

Brief summary

The objective of this study is to determine the role of magnesium on bone and vitamin D metabolism in patients receiving anti-epileptic medications.

Interventions

OTHERNo Intervention. Study is Cross Sectional in nature

No Intervention. Study is cross sectional in nature

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Individuals receiving anti-epileptic drugs as a treatment for epilepsy

Exclusion criteria

* Individuals who are pregnant or breastfeeding, receiving cancer treatments, have liver or kidney diseases, autoimmune diseases, or other diseases that may interfere with vitamin D and magnesium metabolism.

Design outcomes

Primary

Measure	Time frame	Description
Bone mineral density	1 time point - baseline	Will be measured at Tibia, Hip and Total Body using a DXA scan

Secondary

Measure	Time frame	Description
Ionized Magnesium in serum	1 time point - baseline	This will be assayed in the serum
Vitamin D - 25 hydroxy vitamin D	1 time point - baseline	This will be assayed in the serum

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026